Novartis, Glenmark enter partnership to commercialize, distribute respiratory drugs Seebri, Onbrize, Ultibro
Under the terms of the agreement, Novartis will remain the holder of the registration of the drugs Seebri, Onbrize and Ultibro and will be responsible to manufacture them with all technical excellence in line with its global commitment to quality, effectiveness and safety
New Delhi: Drug major Glenmark Pharmaceuticals Monday said its subsidiary Glenmark Farmacutica has entered into an exclusive partnership agreement with Novartis Biosciences SA for three respiratory products in Brazil.
The products involved in the agreement are Seebri (Glycopyrronium bromide), Onbrize (Indacaterol) and Ultibro (combination of Indacaterol and Glycopyrronium), which are indicated for relief of symptoms in adults with chronic obstructive pulmonary disease (COPD).
Glenmark will be responsible for promoting, commercialising and distributing of these products in Brazil, the company added.
This agreement will be effective from July 1, 2019 onwards.
Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said this arrangement with Novartis Biosciences SA will strengthen its respiratory franchise in Brazil.
"This partnership is in line with our vision to expand our respiratory product offerings for patients and prescribers in Brazil and further consolidate our position in this segment," Saldanha said.
Also Read: Novartis’ secret settlement talks revealed in accidental filing: Bloomberg Report
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd